This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate HealthEquity (HQY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights include: HealthEquity, Alarm.com, Stoneridge, Mercer and Bottomline Technologies
These 5 Toxic Stocks Could be Poisoning Your Portfolio
by Zacks Equity Research
Investors who can figure out the overpriced toxic stocks and shun them at the right time are the ones that are likely to benefit.
HealthEquity (HQY) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for June 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q1.
HealthEquity (HQY) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -2.27% and -1.29%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions and Medical-Surgical Solutions segments.
TVTY vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TVTY vs. HQY: Which Stock Is the Better Value Option?
Can HealthEquity (HQY) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is HealthEquity (HQY) Up 15.1% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain HealthEquity Stock for Now
by Zacks Equity Research
Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.
HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.
HealthEquity (HQY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 14.71% and 1.36%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
Why HealthEquity (HQY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why HealthEquity (HQY) Might Surprise This Earnings Season
by Zacks Equity Research
HealthEquity (HQY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HealthEquity (HQY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Up 49% Year to Date: Will the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) benefits from its fast growing healthcare business and international expansion.
5 Top Stocks With Great Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next release.
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results
by Zacks Equity Research
HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.